Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19461960 | 0.82 | HTT (0.64) | HTTGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13306470 | 0.82 | IDO1 (0.46) | MTNR1AMTNR1BIDO1ALDH1A1 | |
| SCHEMBL7894530 | 0.81 | MTNR1A (0.48) | MTNR1AMTNR1BIDO1ALDH1A1 | |
| SCHEMBL21528087 | 0.80 | IDO1 (0.43) | HTTGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL445683 | 0.80 | ALDH1A1 (0.48) | HTTGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24671054 | 0.80 | IDO1 (0.49) | NPC1RAB9ASMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL19462169 | 0.80 | HTT (0.57) | HTTGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22015112 | 0.80 | ALDH1A1 (0.53) | HTTGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18295921 | 0.80 | L3MBTL1 (0.55) | NPC1RAB9ASMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL7018125 | 0.80 | IDO1 (0.58) | HTTGAASMN1; SMN2KDM4EMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017180769-A1 | SMALL MOLECULES FOR IMMUNOGENIC TREATMENT OF CANCER | CAPTEN THERAPEUTICS INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| US-20150328207-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | AUSPEX PHARMACEUTICALS, INC. | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328207-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | SLC18A2, SLC6A2, SLC18A1 | HTT 265/4885GAA 272/4885NPC1 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.